Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
304.55
-9.83 (-3.13%)
Mar 25, 2025, 3:07 PM EDT - Market open
Amgen Revenue
In the year 2024, Amgen had annual revenue of $33.42B with 18.57% growth. Amgen had revenue of $9.09B in the quarter ending December 31, 2024, with 10.86% growth.
Revenue (ttm)
$33.42B
Revenue Growth
+18.57%
P/S Ratio
5.05
Revenue / Employee
$1,193,714
Employees
28,000
Market Cap
163.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
AMGN News
- 7 days ago - Widely used drugs on US imports list from Europe - Reuters
- 12 days ago - UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS - PRNewsWire
- 14 days ago - Stocks beating the stock market's recent Trump slump have this in common - Market Watch
- 14 days ago - Amgen: Riding The MariTide Of Monthly Weight Loss - Seeking Alpha
- 17 days ago - AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS - PRNewsWire
- 18 days ago - NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket - FXEmpire
- 20 days ago - 5 Big Biopharmaceutical Stocks That Are Finding Favor - Barrons
- 20 days ago - Amgen Inc. (AMGN) 45th Annual TD Cowen Health Care Conference (Transcript) - Seeking Alpha